TY - CHAP M1 - Book, Section TI - Hepatocellular Carcinoma A1 - Lee, Sunyoung S. A1 - Zhang, Hao Chi A1 - Cao, Hop S. Tran A1 - Kodali, Sudha A1 - Kuban, Joshua D. A1 - Koay, Eugene J. A1 - Avritscher, Rony A1 - Kaseb, Ahmed O. A2 - Kantarjian, Hagop M. A2 - Wolff, Robert A. A2 - Rieber, Alyssa G. PY - 2022 T2 - The MD Anderson Manual of Medical Oncology, 4e AB - KEY CONCEPTSRisk factors for liver cirrhosis and hepatocellular carcinoma (HCC) include chronic hepatitis B and C infections, metabolic syndrome, and alcohol abuse. Hepatology management of risk factors reduces the risk of cancer recurrence.Treatment for HCC is multidisciplinary and involves hepatology; interventional radiology; and medical, surgical, and radiation oncology.Surgical resection is considered for patients who have small-volume disease without portal hypertension. Those with portal hypertension receive locoregional and/or radiation therapy, and liver transplantation is considered.Systemic therapy is recommended for patients with advanced or metastatic HCC, and locoregional and radiation therapy are combined in eligible patients.Targeted therapy (anti-vascular endothelial growth factor and tyrosine kinase inhibitors) and immune checkpoint inhibitors are two main backbones of systemic therapy. These include sorafenib, lenvatinib, atezolizumab with bevacizumab, nivolumab with and without ipilimumab, pembrolizumab, cabozantinib, regorafenib, and ramucirumab.There are no established guidelines for fibrolamellar HCC (FLHCC) and combined HCC-cholangiocarcinoma (cHCC-CC). Systemic therapy such as 5-fluorouracil plus interferon-α2b for FLHCC and platinum-based chemotherapy for cHCC-CC is combined with surgical resection and locoregional and radiation therapy. SN - PB - McGraw Hill Education CY - New York, NY Y2 - 2024/04/20 UR - hemonc.mhmedical.com/content.aspx?aid=1190835545 ER -